First large-scale population analysis reinforces ketamine's reputation as antidepressant

May 3, 2017
One 10 ml vial of 1000 mg ketamine. Credit: Psychonaught/Wikipedia

Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients. Now, in the largest study of its kind, researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain. They found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.

The study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes—Botox, the reliever diclofenac and the antibiotic minocycline.

"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough," said senior author Ruben Abagyan, PhD, professor of pharmacy. "This study extends small-scale clinical evidence that can be used to alleviate depression, and provides needed solid statistical support for wider clinical applications and possibly larger scale clinical trials."

Abagyan led the study with pharmacy students Isaac Cohen and Tigran Makunts, and Rabia Atayee, PharmD, associate professor of clinical pharmacy, all at Skaggs School of Pharmacy.

The FAERS database contains more than 8 million patient records. The research team focused on in the database who received ketamine, narrowing their study population down to approximately 41,000. They applied a mathematical algorithm to look for statistically significant differences in reported for each patient.

"While most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful side effects, we were looking for the opposite—lack of a symptom," Cohen said.

The team found that the incidence of depression symptoms in patients who took ketamine in addition to other pain therapeutics dropped by 50 percent (with an error margin less than 2 percent) compared to the patients who took any other drug or for pain. Patients who took ketamine also less frequently reported pain and opioid-associated side effects, such as constipation, as compared to patients who received other .

According to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain. That's why they compared ketamine patients with patients taking other pain medications. That control group eliminated the possibility that people who take ketamine have less depression because they have less pain. Abagyan says it's still possible, though unlikely, the effect could be due to a still unidentified confounding factor.

Three other drugs with previously under-appreciated antidepressant effects also emerged from this analysis: Botox, used cosmetically to treat wrinkles and medically to treat migraines and other disorders; diclofenac, a nonsteroidal anti-inflammatory drug (NSAID); and minocycline, an antibiotic.

After the diclofenac finding, Abagyan and team went back and looked at ketamine patients who did not also take NSAIDs and compared them to patients who took any other combination of drugs for pain except NSAIDs. Depression rates in patients taking ketamine remained low.

The researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation. For Botox, the potential mechanism for reducing depression is less clear. The team is now working to separate Botox's beauty effects (which could indirectly make a person feel better emotionally) and its antidepressant effects. To do this, they are first using FAERS data to determine if collagen fillers and other cosmetic treatments similarly affect depression rates.

According to the World Health Organization, more than 300 million people experience depression worldwide. If not effectively treated, depression can become a chronic disease that increases a person's risk of mortality from suicide, heart disease or other factors. Depression is currently treated with five classes of antidepressants, most commonly serotonin reuptake inhibitors.

For financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants. Ketamine is relatively inexpensive and is covered by most health insurance plans if three other antidepressants fail.

"The approach we used here could be applied to any number of other conditions, and may reveal new and important uses for thousands of already approved drugs, without large investments in additional clinical trials," Makunts said.

Explore further: Ketamine no 'wonder drug' for depression

More information: Isaac V. Cohen et al, Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications, Scientific Reports (2017). DOI: 10.1038/s41598-017-01590-x

Related Stories

Ketamine no 'wonder drug' for depression

March 6, 2017

There is no added benefit to using ketamine over a standard anaesthetic during electroconvulsive therapy (ECT) according to new research from the University of Aberdeen.

Antidepressant effects of ketamine

December 8, 2016

New preclinical evidence was put forward by investigators in a series of presentations at the recent meeting of the American College of Neuropsychopharmacology suggest that the a metabolite of ketamine can produce antidepressant-like ...

Ketamine produces rapid-onset antidepressant action

January 5, 2015

(HealthDay)—Ketamine has rapid-onset antidepressant action, although the mechanism of its positive effect is currently unclear, according to research published online Dec. 26 in the Journal of Clinical Pharmacy and Therapeutics.

Recommended for you

Tough times make for more impulsive pre-teens

June 23, 2017

The loss of a grandparent. Marital discord at home. Trouble with peers. When pre-teens are forced to deal with adverse life events such as these they tend to become more impulsive in their decision-making later in life. And ...

Following a friend leads to unsafe driving behavior

June 23, 2017

Have you ever tried following a friend in a car? It can stressful; if you don't keep up, you are likely to get lost. To avoid this, you may make unsafe driving manoeuvres to keep sight of the car ahead.

Video games can change your brain

June 22, 2017

Scientists have collected and summarized studies looking at how video games can shape our brains and behavior. Research to date suggests that playing video games can change the brain regions responsible for attention and ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JamesG
not rated yet May 03, 2017
My wife is a nurse. She has many horror stories of Ketamine being used as anesthesia. Patients who have been given Ketamine as anesthesia often wake up with horrible horrible nightmares, almost to the point of giving the patient PTSD symptoms. Using it as an antidepressant might be different but if anyone you know is going to get it for anesthesia, beg the doctor to use something else.
johnhew
not rated yet May 03, 2017
not really an anesthetic - probably have nightmares too if you wake up in the middle of surgery but are totally immobilized from the paralytics and brain fogged by the amnesic agents.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.